Canaccord Genuity Analysts Give Perrigo (PRGO) a $105.00 Price Target

Canaccord Genuity set a $105.00 price target on Perrigo (NYSE:PRGO) in a report released on Monday. The brokerage currently has a buy rating on the stock.

PRGO has been the topic of several other reports. Cantor Fitzgerald set a $107.00 price objective on Perrigo and gave the company a buy rating in a research report on Friday, January 5th. Oppenheimer reaffirmed a buy rating and set a $98.00 price objective on shares of Perrigo in a research report on Tuesday, February 27th. Finally, Berenberg Bank initiated coverage on Perrigo in a research report on Thursday, February 1st. They set a buy rating and a $117.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $91.88.

How to Become a New Pot Stock Millionaire

Perrigo stock opened at $82.77 on Monday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.96. Perrigo has a one year low of $63.68 and a one year high of $95.93. The firm has a market cap of $11,473.71, a P/E ratio of 16.79, a price-to-earnings-growth ratio of 2.02 and a beta of 0.76.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Thursday, March 1st. The company reported $1.28 EPS for the quarter, beating the consensus estimate of $1.25 by $0.03. Perrigo had a return on equity of 11.54% and a net margin of 2.42%. The company had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.26 billion. During the same period last year, the firm posted $1.24 earnings per share. Perrigo’s revenue was down 3.6% compared to the same quarter last year. equities analysts anticipate that Perrigo will post 5.23 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 20th. Shareholders of record on Friday, March 2nd were given a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 0.92%. This is a boost from Perrigo’s previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 1st. Perrigo’s dividend payout ratio (DPR) is presently 15.42%.

In other news, CEO Uwe Roehrhoff bought 7,500 shares of the company’s stock in a transaction on Monday, March 5th. The shares were acquired at an average cost of $81.85 per share, with a total value of $613,875.00. Following the completion of the transaction, the chief executive officer now owns 4,900 shares of the company’s stock, valued at approximately $401,065. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 6.90% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of PRGO. Russell Investments Group Ltd. raised its stake in shares of Perrigo by 38.0% in the third quarter. Russell Investments Group Ltd. now owns 18,889 shares of the company’s stock worth $1,599,000 after buying an additional 5,203 shares during the period. Wells Fargo & Company MN raised its stake in shares of Perrigo by 17.2% in the third quarter. Wells Fargo & Company MN now owns 157,409 shares of the company’s stock worth $13,324,000 after buying an additional 23,068 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Perrigo by 40.8% in the third quarter. Dimensional Fund Advisors LP now owns 622,690 shares of the company’s stock worth $52,699,000 after buying an additional 180,348 shares during the period. Allianz Asset Management GmbH bought a new position in shares of Perrigo in the third quarter worth about $217,000. Finally, Highbridge Capital Management LLC bought a new position in shares of Perrigo in the third quarter worth about $442,000. 79.16% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at

About Perrigo

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.

Analyst Recommendations for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with's FREE daily email newsletter.

Leave a Reply